Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14415707 | 1.00 | AOC3 (0.41) | AOC3HDAC4HDAC7HDAC5IDO1 | |
| SCHEMBL14415710 | 1.00 | AOC3 (0.41) | AOC3HDAC4HDAC7HDAC5IDO1 | |
| SCHEMBL31377021 | 0.81 | HDAC4 (0.41) | AOC3HDAC4HDAC7HDAC5IDO1 | |
| SCHEMBL2339913 | 0.81 | HDAC4 (0.41) | AOC3HDAC4HDAC7HDAC5IDO1 | |
| SCHEMBL3556521 | 0.79 | HDAC4 (0.42) | AOC3HDAC4HDAC7HDAC5IDO1 | |
| SCHEMBL10442326 | 0.78 | AOC3 (0.46) | AOC3HDAC4HDAC7HDAC5IDO1 | |
| SCHEMBL8657495 | 0.76 | HDAC4 (0.43) | AOC3HDAC4HDAC7HDAC5IDO1 | |
| Ammonia Solution, Strong SCHEMBL6001272 | 0.76 | AOC3 (0.45) | AOC3HDAC4HDAC7HDAC5IDO1 | |
| SCHEMBL27168775 | 0.76 | TRPA1 (0.48) | KDM4E | |
| SCHEMBL16570971 | 0.75 | CES2 (0.49) | AOC3HDAC4HDAC7HDAC5IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7268166-B2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1749522-A2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2007-02-07 | — | — | EP | disclosed |
| US-7087765-B2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-20060142594-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | MUELLER ALAN L | 2006-06-29 | — | — | US | disclosed |
| US-20040171670-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. | 2004-09-02 | — | — | US | disclosed |
| US-6750244-B2 | NERVOUS SYSTEM DISORDERS | NPS PHARMACEUTICALS, INC. | 2004-06-15 | — | — | US | disclosed |
| US-20020004522-A1 | Nervous system disorders | NPS PHARMACEUTICALS, INC. | 2002-01-10 | — | — | US | disclosed |
| US-6306912-B1 | POLYAMINO CARBONYLAMINO ALKYL FLUORO SUBSTITUTES INDOLE COMPOUNDS | NPS PHARMACEUTICALS, INC. | 2001-10-23 | — | — | US | disclosed |
| EP-1123922-A2 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NPS PHARMACEUTICALS, INC. (US) | 2001-08-16 | — | — | EP | disclosed |
| EP-0743853-B1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS AND DISEASES | NPS PHARMA INC (US) | 2001-05-02 | — | — | EP | disclosed |
| US-6211245-B1 | DRUGS FOR CONTROLLING CALCIUM MODULATORS | NPS PHARMACEUTICALS, INC. | 2001-04-03 | — | — | US | disclosed |
| US-6071970-A | FOR TREATING PATIENTS HAVING NEUROLOGICAL DISEASE OR DISORDER, SUCH AS STROKE, HEAD TRAUMA, SPINAL CORD INJURY, EPILEPSY, ANXIETY, OR NEURODEGENERATIVE DISEASES SUCH AS ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, PARKINSON'S DISEASE | NPS PHARMACEUTICALS, INC. (US) | 2000-06-06 | — | — | US | disclosed |
| US-6051610-A | COMPOUNDS USEFUL AS NEUROPROTECTANTS, ANTICONVULSANTS, ANXIOLYTICS, ANALGESICS, MUSCLE RELAXANTS OR ADJUVANTS TO GENERAL ANESTHETICS | NPS PHARMACEUTICALS, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| US-6017965-A | TREATING STROKE, HEAD TRAUMA, SPINAL CORD INJURY, SPINAL CORD ISCHEMIA, ISCHEMIA- OR HYPOXIA-INDUCED NERVE CELL DAMAGE, EPILEPSY, ANXIETY, NEUROPSYCHIATRIC OR COGNITIVE DEFICITS DUE TO ISCHEMIA OR HYPOXIA | NPS PHARMACEUTICALS, INC. (US) | 2000-01-25 | — | — | US | disclosed |
| EP-0831799-A1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS | NPS PHARMACEUTICALS, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040097-A1 | COMPOUNDS ACTIVE AT A NOVEL SITE ON RECEPTOR-OPERATED CALCIUM CHANNELS USEFUL FOR TREATMENT OF NEUROLOGICAL DISORDERS | NPS PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142594-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NCS1, ATP2A1, CACNA1D | AOC3 2484/4885HDAC4 975/4885HDAC7 1261/4885 |
| US-20040171670-A1 | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases | NCS1, ATP2A1, CACNA1D | AOC3 2484/4885HDAC4 975/4885HDAC7 1261/4885 |
| US-20020004522-A1 | Nervous system disorders | HIF1A, PYGB, LDHB | AOC3 2232/4885HDAC4 353/4885HDAC7 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.